<SEC-DOCUMENT>0001178913-23-002170.txt : 20230606
<SEC-HEADER>0001178913-23-002170.hdr.sgml : 20230606
<ACCEPTANCE-DATETIME>20230606071506
ACCESSION NUMBER:		0001178913-23-002170
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20230606
FILED AS OF DATE:		20230606
DATE AS OF CHANGE:		20230606

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sol-Gel Technologies Ltd.
		CENTRAL INDEX KEY:			0001684693
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38367
		FILM NUMBER:		23994874

	BUSINESS ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
		BUSINESS PHONE:		97289313433

	MAIL ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2329857.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div style="text-align: center; line-height: 1.25; font-weight: bold;">
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"><br>
    <font style="font-size: 14pt;">UNITED STATES</font></div>
  <div style="text-align: center;" class="BRPFPageNumberArea">
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
      <div style="line-height: 1.25; font-weight: bold;">Washington, D.C. 20549</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25; font-size: 14pt;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">FORM&#160;6-K</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Report of Foreign Private Issuer</div>
      <div style="line-height: 1.25; font-weight: bold;">Pursuant to Rule&#160;13a-16&#160;or&#160;15d-16</div>
      <div style="line-height: 1.25; font-weight: bold;">Under the Securities Exchange Act of 1934</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">For the month of June 2023</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">Commission File Number 001-38367</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
      <div style="line-height: 1.25;">(Translation of registrant&#8217;s name into English)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">7 Golda Meir Street</div>
      <div style="line-height: 1.25; font-weight: bold;">Ness Ziona 7403650, Israel</div>
      <div style="line-height: 1.25;">(Address of principal executive offices)</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form&#160;20-F&#160;or Form&#160;40-F.</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;">Form&#160;20-F <font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9746;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form&#160;40-F&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule
        101(b)(1):&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; text-indent: 24.5pt; line-height: 1.25;">Indicate by check mark if the registrant is submitting the Form&#160;6-K&#160;in paper as permitted by Regulation&#160;S-T&#160;Rule
        101(b)(7):&#160;&#160;<font style="font-family: 'Segoe UI Symbol', sans-serif;">&#9744;</font></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%%%--></div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25; font-weight: bold;">INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: left; line-height: 1.25;">On June 06, 2023, Sol-Gel Technologies Ltd. (the &#8220;Company&#8221;) issued a press release announcing Licensing Agreements to Commercialize TWYNEO&#174;
      and EPSOLAY&#174; in Canada.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: left; line-height: 1.25;">Attached hereto is the following exhibit:</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: left; line-height: 1.25;"><a href="exhibit_99-1.htm">Exhibit 99.1</a>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<a href="exhibit_99-1.htm">Press release dated June 6, 2023</a></div>
    <div style="text-align: left; line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">Exhibit 99.1 is hereby incorporated by reference into
        the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915 and 333-270477) and its Registration Statement on Form F-3 (Registration No. 333-264190).</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; font-weight: bold;">SIGNATURES</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: left; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its
        behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
    </div>
    <table cellspacing="0" cellpadding="0" border="0" id="z6eedc6535dda48a3aba31a1d4abf08c7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="vertical-align: top;" colspan="2">
            <div style="line-height: 1.25; font-weight: bold;">SOL-GEL TECHNOLOGIES LTD.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: middle;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">Date:&#160; June 6, 2023</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">By:</div>
          </td>
          <td style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
            <div style="line-height: 1.25;">/s/ Gilad Mamlok</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Gilad Mamlok</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 4%; vertical-align: top;">
            <div style="line-height: 1.25;">&#160;</div>
          </td>
          <td style="width: 46%; vertical-align: top;">
            <div style="line-height: 1.25;">Chief Financial Officer</div>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div><font style="font-family: 'Times New Roman',Times,serif; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font> </div>
    <div> </div>
    <div style="line-height: 1.25;">
      <div style="line-height: 1.25">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: ZKG
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div style="text-align: right;"><font style="font-style: normal;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u></font><br>
  </div>
  <div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <table cellspacing="0" cellpadding="0" id="z9b65dbe7985440e9a7e3c81e159708f1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top;">
            <div style="line-height: 1.25;"><img src="image00002.jpg"></div>
          </td>
          <td style="width: 50%; vertical-align: middle;">
            <div style="text-align: right; line-height: 1.25;"><img width="259" height="44" src="image1.jpg"></div>
          </td>
        </tr>

    </table>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Sol-Gel and Searchlight Pharma Announce Licensing Agreements to </div>
    <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Commercialize TWYNEO<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> and EPSOLAY<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> in Canada</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zf71921e9f96c4940ad0480fc2bf863fe" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-style: italic;">Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both
                drugs, combined, plus additional royalties ranging from low double-digits to high-teens</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z49ae166f33b948df8b9827f47059208d" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-style: italic;">Non-dilutive capital strengthens Sol-Gel&#8217;s balance sheet</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z559eb3fcaa3b4df3a64b02b92ebfae45" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top; text-align: right;">
              <div style="text-align: left; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25; font-style: italic;">Searchlight Pharma anticipates filing of Canadian regulatory submissions in early 2024, and for both
                products to become foundational pieces of its dermatology pipeline and portfolio</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">NESS ZIONA, Israel and MONTREAL, Canada, June 6, 2023 -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (&#8220;Sol-Gel&#8221;), an Israel-based
      dermatology company and Searchlight Pharma Inc. (&#8220;Searchlight&#8221;), a private Canadian specialty pharmaceutical company, today announced the signing of exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. TWYNEO and EPSOLAY are
      two innovative, large-market, dermatology products that were developed by Sol-Gel. Both products recently launched in the U.S., and Searchlight is to commercialize them in Canada over a fifteen-year term that is renewable for subsequent five-year periods.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="zcecc37e131fb450fa36527f45ea7d922" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 8pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">TWYNEO (tretinoin, 0.1%, and benzoyl peroxide, 3%, cream) is used for the treatment of acne vulgaris&#160;in adults and pediatric patients 9&#160;years of age and older.</div>
            </td>
          </tr>

      </table>
    </div>
    <div>
      <table cellspacing="0" cellpadding="0" id="z7799fa704cfd4771837788d79010d771" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin-bottom: 8pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt; vertical-align: top;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">EPSOLAY (benzoyl peroxide, 5%, cream) is used for the treatment of inflammatory lesions of rosacea in adults.</div>
            </td>
          </tr>

      </table>
    </div>
    <div style="text-align: justify; line-height: 1.25;">&#8220;We are pleased to partner with a leading and dynamic specialty pharmaceutical company, Searchlight Pharma, to introduce our two
      innovative dermatology drugs to Canadian patients and to generate non-dilutive capital for our shareholders,&#8221; stated Alon Seri-Levy, Ph.D., Chief Executive Officer of Sol-Gel. &#8220;With this partnership, we look forward to expanding our strong commercial
      presence in North America and further strengthening our growing revenue base.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">As part of the agreement terms, Sol-Gel will receive up to $11 million in potential upfront payments and regulatory and sales milestones
      for both drugs, combined. In addition, Sol-Gel will be entitled to royalty percentages of all Canadian net sales ranging from low-double-digits to high teens.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25;">Mark Nawacki, President and Chief Executive Officer, of Searchlight Pharma Inc., commented, &#8220;TWYNEO and EPSOLAY are valuable additions
      to our growing portfolio in line with our philosophy to acquire innovative and unique specialty healthcare products in therapeutic areas within our strategic interest. Both products have had encouraging uptake by physicians in the U.S. over the past
      year, and we look forward to commercializing them for patients in Canada.&#8221;</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Searchlight will be responsible for obtaining and maintaining any regulatory approvals required to market and sell the drugs in Canada,
      with support from Sol-Gel.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Dr. Seri-Levy continued, &#8220;Searchlight has repeatedly ranked among the top growth companies in Canada and is dedicated to improving
      health through the acquisition and commercialization of differentiated and unique healthcare products. We look forward to collaborating with Searchlight to maximize the presence of our two unique drugs, TWYNEO and EPSOLAY, in Canada, a leading
      commercial territory.&#8221;</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About TWYNEO</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% is
        used for the topical treatment of acne vulgaris in adults and pediatric patients 9&#160;years of age and older.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">TWYNEO utilizes a proprietary, patented technology where tretinoin and BPO are encapsulated within silica-based microcapsules to create
      a barrier between the medication and the skin. The patented microencapsulation technology in TWYNEO Cream segregates and envelopes the active ingredients in silica core shells (microcapsules) so that tretinoin is protected from the oxidizing effects
      of BPO, allowing the combination of both drugs into one product and gradual release onto the skin.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Sol-Gel Technologies&#160;received U.S. Food and Drug Administration (&#8220;FDA&#8221;) approval for TWYNEO Cream on&#160;July 27, 2021, and has granted
      exclusive rights to Galderma to commercialize the treatment in the&#160;U.S.</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About EPSOLAY</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">EPSOLAY is a topical cream containing encapsulated benzoyl peroxide (BPO), 5%, for the treatment of inflammatory lesions of rosacea in
      adults.&#160;EPSOLAY utilizes a proprietary, patented technology to encapsulate BPO within silica-based microcapsules to create a barrier between the medication and the skin.&#160;The silica-based shell is designed to slowly release BPO over time to provide a
      tolerable and effective treatment.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Sol-Gel Technologies received FDA approval for EPSOLAY Cream on&#160;April 22, 2022,&#160;and has granted exclusive rights to Galderma to
      commercialize the treatment in the U.S.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="line-height: 1.25;">
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Searchlight Pharma Inc.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">Searchlight Pharma Inc., headquartered in Montreal, is a
          leading Canadian-based specialty healthcare company that executes best-in-class search, acquisition, commercialization, and focused development of innovative and unique specialty healthcare products. Following its acquisition of Miravo Healthcare
          in March 2023, Searchlight&#8217;s core promoted products now focus on women&#8217;s health, dermatology, allergy, pain management and hospital specialty markets, and its team is committed to improving people&#8217;s lives by bringing the right products to market.
          Follow Searchlight, learn more about what it does, and get to know its product portfolio at&#160;<u>www.searchlightpharma.com</u>.&#160;</div>
      <div style="line-height: 1.25">&#160;</div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">About Sol-Gel Technologies</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">Sol-Gel Technologies, Ltd. is a dermatology company focused on identifying, developing and commercializing or partnering drug products
      for the treatment of skin diseases. Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, which is approved by the FDA for the treatment of
      inflammatory lesions of rosacea in adults. Both drugs are exclusively licensed to and commercialized by Galderma in the U.S.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">The Company&#8217;s pipeline includes Orphan Drug candidate, SGT-610 under investigation for the prevention of new basal cell carcinomas in
      Gorlin syndrome patients, and also includes topical drug candidate SGT-210 under investigation for the treatment of rare skin keratodermas.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">For additional information, please visit <u>www.sol-gel.com</u>.</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Forward-Looking Statements</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25; font-style: italic;">This press release contains &#8220;forward-looking statements&#8221; within the meaning of the Private Securities Litigation
      Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to the benefits we expect to receive under our agreement
      with Searchlight Pharma and the commercial acceptance, profitability and reimbursement of TWYNEO and EPSOLAY. These forward-looking statements include information about possible or assumed future results of our business, financial condition, results
      of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or
      the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management&#8217;s current expectations and are subject to risks and uncertainties that could cause
      actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to, the risk that we may not receive the
      benefits we expect to receive under our agreement with Searchlight Pharma, the risk that the commercial acceptance, profitability and reimbursement of TWYNEO and EPSOLAY will not be as anticipated, risks that our cash runway will be shorter than
      expected, risks relating to the current global macroeconomic climate as well as the following factors: (i) the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the
      adequacy of our liquidity to pursue our complete business objectives; (ii) our ability to complete the development of our product candidates; (iii) our ability to find suitable co-development partners; (iv) our ability to obtain and maintain
      regulatory approvals for our product candidates in our target markets, the potential delay in receiving such regulatory approvals and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory
      approval is obtained; (v) our collaborators&#8217;<strike>&#160;</strike>ability to commercialize our pharmaceutical product candidates; (vi) our ability to obtain and maintain
      adequate protection of our intellectual property; (vii) our collaborators&#8217;<strike>&#160;</strike>ability to manufacture our product candidates in commercial quantities, at
      an adequate quality or at an acceptable cost; (viii) our collaborators&#8217; ability to establish adequate sales, marketing and distribution channels; (ix) acceptance of our product candidates by healthcare professionals and patients; (x) the possibility
      that we may face third-party claims of intellectual property infringement; (xi) the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; (xii) intense competition
      in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; (xiii) potential product
      liability claims; (xiv) potential adverse federal, state and local government regulation in the United States, Europe or Israel; and (xv) loss or retirement of key executives and research scientists. These and other important factors discussed in the
      Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 10, 2023, as amended, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the
      forward-looking statements made in this press release. Except as required by law, we undertake no obligation to update any forward-looking statements in this press release.</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="text-align: justify; line-height: 1.25;">For further information, please contact:</div>
    <div style="line-height: 1.25">&#160;</div>
    <div style="line-height: 1.25"><font style="font-weight: bold;">Investors: </font><br>
    </div>
    <div style="line-height: 1.25;">Irina Koffler</div>
    <div style="line-height: 1.25;">Investor relations, LifeSci Advisors<br>
      <u>ikoffler@lifesciadvisors.com</u></div>
    <div style="line-height: 1.25;">+1 917 734 7387</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Sol-Gel Technologies</div>
    <div style="text-align: justify; line-height: 1.25;">Gilad Mamlok</div>
    <div style="text-align: justify; line-height: 1.25;">Chief Financial Officer</div>
    <div style="text-align: justify; line-height: 1.25;"><u>gilad.mamlok@sol-gel.com</u></div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Searchlight Pharma Inc.</div>
    <div style="text-align: justify; line-height: 1.25;">Mark Nawacki</div>
    <div style="text-align: justify; line-height: 1.25;">President &amp; CEO</div>
    <div style="line-height: 1.25;"><br style="line-height: 1.25;">
    </div>
    <div style="text-align: justify; line-height: 1.25;">Jesse Ledger</div>
    <div style="text-align: justify; line-height: 1.25;">Chief Strategy &amp; Corporate Development Officer</div>
    <div style="text-align: justify; line-height: 1.25;"> <br>
    </div>
    <div style="text-align: justify; line-height: 1.25;"><u>info@searchlightpharma.com</u></div>
    <div style="text-align: justify; line-height: 1.25;"><u> <br>
      </u></div>
    <div style="text-align: justify; line-height: 1.25;">
      <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"><u> </u></div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image1.jpg
<TEXT>
begin 644 image1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !F E,# 2(  A$! Q$!_\0
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MJMJ,CQ:7=R1L5=(792.Q"FK-4]5_Y ]]_P!>\G_H)K=['LS^%GB)\9>(<_\
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MEMITG@D:.5#E70X*GV-:?_"4Z_\ ]!B^_P"_[?XUT5\.ZK33$G8^O**^0_\
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M4N44]S"5>A"3YI),ZFO(_BG_ ,A^V_Z]Q_,UZS%*LT*2H<HZAE/L:\F^*?\
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M*^GFB6W9F7RL<Y ]?I4T9J%128/8^4J^KOA]_P B#HW_ %[BN2_X49H'_/\
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M_B&R2UN9'1%?>"G7-<W_ ,*MTG_GZN?T_P **E.4I70\=@:U:MSP6AJ> /\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" !" (<# 2(  A$! Q$!_\0
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
